Lean Semaglutide when…
- Cardiovascular history matters — semaglutide has dedicated CV outcome data (SELECT)
- You want an oral option (Rybelsus) or the longest real-world track record
- Insurance coverage favors Ozempic or Wegovy in your plan
HEAD TO HEAD
Semaglutide vs Tirzepatide.
Tirzepatide (Mounjaro, Zepbound) achieved greater average weight loss in trials — up to 20.9% at 72 weeks (SURMOUNT-1) vs 14.9% at 68 weeks for semaglutide 2.4 mg (STEP-1). Semaglutide (Ozempic, Wegovy, Rybelsus) has a longer real-world track record, proven cardiovascular benefit (SELECT), and an oral option. Both are weekly injectables at heart; tirzepatide is a dual GIP/GLP-1 agonist. Which is right for you is a clinical decision — GLP AI tracks either.
Education only, from FDA labels and published trials — never medical advice. Which medication is right for you is a decision for you and your clinician.
VERIFIEDGLP AISemaglutide vs TirzepatideSources verified July 15, 2026
1M+Downloads across iOS, Android & web
4.9★App Store rating
iPhone + AndroidApp Store + Google Play
Either oneGLP AI tracks both — shots or pills
FDA-labeledFacts from prescribing information, cited
One timelineDoses · meals · symptoms · levels
AT A GLANCE
When each one makes sense.
Lean Tirzepatide when…
- Maximum trial-measured weight loss is the priority (~21% vs ~15%)
- You didn't tolerate or plateaued on semaglutide (a common clinical switch)
- A1C reduction head-to-head matters — tirzepatide beat semaglutide 1 mg in SURPASS-2
These are talking points for a clinician conversation, not a prescription.
SIDE BY SIDE
Semaglutide vs Tirzepatide, feature by feature.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Manufacturer | Novo Nordisk — sold as Ozempic, Wegovy, and Rybelsus | Eli Lilly — sold as Mounjaro and Zepbound |
| FDA approval | FDA-approved as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management); also widely prescribed as compounded semaglutide | FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management); also prescribed as compounded tirzepatide |
| Form & frequency | Injection, weekly | Injection, weekly |
| Dose range | 0.25 mg → 2.4 mg | 2.5 mg → 15 mg |
| Half-life | ~7 days | ~5 days |
| Headline trial result | Up to 14.9% mean body-weight reduction at 68 weeks (semaglutide 2.4 mg); 20% reduction in major cardiovascular events in SELECT | Up to 20.9% mean weight loss at 72 weeks on 15 mg (SURMOUNT-1); superior A1C reduction vs semaglutide 1 mg (SURPASS-2) |
| Most common side effect | Nausea (16–44% (varies by brand and dose)) | Nausea (12–29% (varies by brand and dose)) |
| Tracked by GLP AI | ✅ Doses, meals, side effects, levels | ✅ Doses, meals, side effects, levels |
Sources: Ozempic Prescribing Information (Novo Nordisk) · Mounjaro Prescribing Information (Eli Lilly) · trials as cited on each medication's page.
WHICHEVER YOU CHOOSE
Track either with GLP AI.
Doses (shots or pills), a 0–100 GLP-1 Meal Score for every meal, side effects beside dose days, and an estimated medication level chart — the journey looks the same in GLP AI no matter which medication you and your clinician pick.
THE QUICK ANSWERS
Semaglutide vs Tirzepatide — FAQs.
What is the difference between Semaglutide and Tirzepatide?+
Tirzepatide (Mounjaro, Zepbound) achieved greater average weight loss in trials — up to 20.9% at 72 weeks (SURMOUNT-1) vs 14.9% at 68 weeks for semaglutide 2.4 mg (STEP-1). Semaglutide (Ozempic, Wegovy, Rybelsus) has a longer real-world track record, proven cardiovascular benefit (SELECT), and an oral option. Both are weekly injectables at heart; tirzepatide is a dual GIP/GLP-1 agonist. Which is right for you is a clinical decision — GLP AI tracks either.
How are Semaglutide and Tirzepatide dosed?+
Semaglutide: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.0 mg → 2.4 mg, weekly (injection). Tirzepatide: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, weekly (injection). Escalation schedules come from each FDA label; your prescriber sets the pace.
How long do Semaglutide and Tirzepatide stay in your system?+
Semaglutide (semaglutide) has a ~7 days half-life; Tirzepatide (tirzepatide) has a ~5 days half-life. That difference shapes dosing frequency and how missed doses feel — GLP AI's medication level chart visualizes both.
Which has more side effects — Semaglutide or Tirzepatide?+
Both are GI-first. Semaglutide's label lists nausea at 16–44% (varies by brand and dose); Tirzepatide's lists nausea at 12–29% (varies by brand and dose). Cross-trial numbers aren't directly comparable, and individual tolerance varies — tracking your own timeline is more useful than comparing labels.
Can I switch between Semaglutide and Tirzepatide?+
Switching between GLP-1 medications is common and is entirely a decision for your prescriber, who will map an equivalent starting dose. A tracked history — doses, side effects, weight — makes that conversation concrete.
Which is right for me — Semaglutide or Tirzepatide?+
That's a clinical decision based on your health history, goals, tolerance, and coverage. This page is education, not medical advice. Whichever you and your clinician choose, GLP AI tracks it.
How do I track Semaglutide or Tirzepatide?+
GLP AI tracks both: doses (shots or pills), a 0–100 GLP-1 Meal Score for every meal, side effects beside dose days, and an estimated medication level chart — one timeline either way.
Is tirzepatide stronger than semaglutide?+
In trials, tirzepatide produced greater average weight loss (SURMOUNT-1: up to 20.9% at 72 weeks) than semaglutide 2.4 mg (STEP-1: 14.9% at 68 weeks), and beat semaglutide 1 mg on A1C in SURPASS-2. Individual response varies widely — averages aren't destinies.
Why do people call tirzepatide a "dual agonist"?+
Semaglutide activates the GLP-1 receptor; tirzepatide activates both GIP and GLP-1 receptors. The dual mechanism is one hypothesis for its larger average effect in trials.
KEEP EXPLORING
Go further with GLP AI.
Track it once. Understand it forever.
Whichever medication wins, GLP AI tracks it — free to start.